On the other hand, the frequency of epidermal growth factor receptor (EGFR) mutations, ALK, and ROS1 translocations are usually lower or even negative compared with other subtypes of adenocarcinomas, thus rendering them ineligible for tyrosine kinase, so their response to chemotherapy is modest [5,7,8,9]. Here, EGFR is linked to adenocarcinoma.